Moreover, while the available Prostate‐Specific Antigen (PSA)‐based tests are of poor specificity in the detection of PCa, investigating the levels of post‐translational modifications and proteoforms of such proteins as PSA and prostate‐specific membrane antigen (PSMA) in a targeted manner in plasma, in addition to the described here EV sub‐population‐based profiling, may provide more specificity and sensitivity in diagnostic and prognostic applications. The gene discussed is PROS1; the disease is posterior cortical atrophy.